Qyuns Therapeutics Co., Ltd. announced that on 8 July 2026 it repurchased 600 H-shares on the Hong Kong Stock Exchange at a fixed price of HKD 15.70 per share, bringing the total cash consideration to HKD 9,420.

The repurchased shares—equivalent to 0.00027 % of the company’s 223.37 million issued shares (excluding treasury shares) prior to the transaction—have been retained as treasury shares, lifting the treasury-share balance to 3.70 million. After the buyback, the company’s total issued share count remains unchanged at 227.07 million.

The repurchase forms part of a mandate approved on 29 May 2026 that authorises Qyuns Therapeutics to buy back up to 22.44 million shares. Cumulative repurchases under this mandate now stand at 990,200 shares, representing 0.4413 % of the outstanding share capital at the date the mandate was granted.

In line with Hong Kong listing regulations, Qyuns Therapeutics is subject to a moratorium on issuing new shares or transferring treasury shares until 7 August 2026.